08:00 , Jan 11, 2016 |  BioCentury  |  Strategy

Growing up Galapagos

With a new partner for filgotinib, Galapagos N.V. is poised to enter Phase III testing for the first time, after a five-year period of Phase II disappointments and scuttled deals. The new deal with Gilead...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

GLPG0259: Phase II discontinued

Galapagos discontinued a double-blind, placebo-controlled, international Phase II trial of GLPG0259 after an analysis by an interim review committee showed "limited efficacy potential" of the compound. The committee analyzed unblinded safety and efficacy data from...
00:43 , Apr 16, 2011 |  BC Extra  |  Clinical News

Galapagos falls after stopping RA trial

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) fell EUR 2.89 (24%) to EUR 9.31 on Friday after discontinuing a Phase II trial of GLPG0259 to treat rheumatoid arthritis. The company said an analysis by an interim review committee...
00:52 , Oct 20, 2010 |  BC Extra  |  Financial News

Galapagos raises EUR 28.7 million

Galapagos N.V. (Euronext:GPLG; Pink:GLPYY) raised EUR 28.7 million ($39.8 million) through the sale of 2.4 million shares at EUR 12 per share in a private placement. The EUR 12 sale price is an 8% discount...
01:02 , Oct 19, 2010 |  BC Extra  |  Financial News

Galapagos to sell shares

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said late Monday that it plans to sell up to 2.4 million shares on NYSE Euronext Brussels. If sold in full at Monday's close of EUR 13.10, the company would raise...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

GLPG0259: Phase II started

Galapagos began a 12-week, double-blind, placebo-controlled, European Phase II trial to evaluate 3 doses of oral GLPG0259 plus once-daily methotrexate in 180 patients. J&J's Janssen Pharmaceutica N.V. subsidiary has an exclusive option to license the...
08:00 , Mar 1, 2010 |  BC Week In Review  |  Clinical News

GLPG0259: Phase I data

A double-blind, placebo-controlled, multiple ascending-dose, Belgian Phase I trial in 24 healthy volunteers showed that 25, 50 and 75 mg oral GLPG0259 plus methotrexate for 14 days were safe and had a pharmacokinetic profile that...
00:23 , Oct 17, 2009 |  BC Extra  |  Financial News

Galapagos raises EUR 18.2 million

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) raised EUR 18.2 million ($26.7 million) through the sale of 2.1 million shares at EUR 8.55 in a follow-on. Galapagos proposed the offering late Thursday, when its share price was EUR...
00:19 , Oct 16, 2009 |  BC Extra  |  Financial News

Galapagos planning offering

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said late Thursday that it plans to sell up to 2.1 million shares in an offering. If sold in full at Galapagos' Thursday close of EUR 8.98, the company would raise...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Clinical News

GLPG0259: Phase I started

Galapagos began a double-blind, placebo-controlled, multiple ascending-dose, Belgian Phase I trial to evaluate 25, 50 and 75 mg of oral GLPG0259 plus methotrexate for 14 days in 24 healthy volunteers. J&J's Janssen Pharmaceutica N.V. subsidiary...